<DOC>
	<DOCNO>NCT01596257</DOCNO>
	<brief_summary>The purpose study find get blood stem cell transplant donor stem cell give several day well get blood stem cell transplant donor stem cell give 1 day . We want find procedure result improve recovery blood immune function transplant . When donor stem cell give various day mice , blood immune system recovery quicker .</brief_summary>
	<brief_title>Bulk Versus Fractionated Stem Cell Infusions Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation</brief_title>
	<detailed_description>This complex study involve various intervention , Intervention # 1 : Donor Initial Stem Cell Collection ; Intervention # 2 : Stem Cell Product Initial Processing Orders ; Intervention # 3 Patient Admission Transplantation ; Intervention # 4 : Stem cell infusion ; Intervention # 5 : Post infusion follow ; Intervention # 6 : Off Study Patient Donor Evaluation . Patients whose donor fail collect appropriate number cell receive cell bulk infusion . These patient continue receive transplant protocol replace arm reach target accrual .</detailed_description>
	<criteria>Patients consider candidate allogeneic stem cell transplantation treatment follow hematologic disorder : Acute Leukemia Myelodysplastic syndrome Other myeloproliferative disorder ( i.e . myelofibrosis , chronic myelomonocytic leukemia , chronic myelogenous leukemia ) Non Hodgkins Lymphoma Hodgkins Disease Multiple Myeloma Age include birth &lt; 75 year old . Patients must Karnofsky ( adult ) Lansky ( pediatric ) Performance Status &gt; 70 % Patients must adequate organ function measure : Cardiac : asymptomatic symptomatic LVEF rest must &gt; 40 % Hepatic : &lt; 5x ULN ALT &lt; 1.5 total serum bilirubin , unless congenital benign hyperbilirubinemia . Renal : serum creatinine &lt; 1.5 mg/dl serum creatinine outside normal range , CrCl &gt; 40 ml/min ( measure calculated/estimated ) Pulmonary : asymptomatic symptomatic , DLCO &gt; 40 % predict ( correct hemoglobin ) . Female patient pregnant breastfeeding . Active viral , bacterial fungal infection Patient seropositive HIVI/II ; HTLV I/II Presence leukemia CNS Candidate protocol high priority . For purpose study , follow protocol consider high priority : 10051 Donor HLA compatible relate unrelated donor , ( i.e . fully match unmanipulated graft 12 HLA allele disparate donor CD34 select graft ) . Meets criteria outline FACTapproved SOP `` DONOR EVALUATION AND SELECTION FOR ALLOGENEIC TRANSPLANTATION '' Blood Marrow Transplant Program Manual , document E1 see http : //mskweb5.mskcc.org/intranet/html/80312.cfm Donor must adequate peripheral venous catheter access leukapheresis must agree placement central catheter . Wt &gt; 25kg Donor Evidence active infection ( include urinary tract infection , upper respiratory tract Infection ) viral hepatitis exposure ( screen ) , unless HBS Ab+ HBV DNA negative . Medical physical reason make donor unlikely tolerate cooperate growth factor therapy leukapheresis . Factors place donor increase risk complication leukapheresis GCSF therapy ( e.g. , autoimmune disease , sickle cell trait , symptomatic coronary artery disease require therapy ) . Pregnancy ( positive serum urine Î²HCG ) breastfeeding . Women childbearing age must avoid become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CliniMACS-CD34 Reagent System</keyword>
	<keyword>Acute Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Non Hodgkins Lymphoma</keyword>
	<keyword>Hodgkins Disease</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>12-016</keyword>
</DOC>